Mydayis

Shire launches ADHD med Mydayis as it weighs a neuroscience exit

Shire has rolled out Mydayis, its new Adderall formulation, at a list price of $271 per month. The aim? Hitting $500 million in sales.

Eric Sagonowsky Aug 28, 2017 10:15am

Shire hints at ADHD spinoff, but could someone buy the neuro group?

Aug 3, 2017 12:00pm

Shire scores FDA nod for Mydayis, its latest Adderall iteration

Jun 21, 2017 10:32am